Moffitt logo

Articles related to Research

Moffitt Cancer Center Joins Weill Cornell Medicine and University of North Carolina to Improve HIV-Related Cancer Care Abroad

The institutions received a $3.5 million grant from the National Cancer Institute to support their work Read More

Using A Seaweed Sugar to Trigger Immune Responses That Suppress Melanomas

Moffitt researchers discovered that administering oral L-fucose triggers potent antitumor immune responses that suppress tumors and enhance immunotherapies Read More

Moffitt Researchers Develop Tool to Measure Patient Health and Well-Being after Radionuclide Therapy

The FACT-RNT tool assesses prostate cancer patient-reported outcomes with the goal of guiding treatment, improving care Read More

Moffitt Researchers Develop Technology that Allows First Visualization of Radiation Therapy in a Patient in Real Time

Ionizing radiation acoustic imaging technology can help guide treatment and improve efficacy Read More

Connecting Spanish-Speaking Patients with Quitline Improves Quit Rates

New Moffitt study shows patients who proactively received Quitline treatment in Spanish had better engagement and smoking abstinence rates than those who received treatment in English Read More

Moffitt Researchers Discover Connection Between Stress-Activated Signaling and Immune Cell Evasion in Melanoma

Inhibition of the stress-activated survival protein PERK promotes anti-tumor immunity Read More

Moffitt Receives $3.7 Million Grant to Increase Minority Accrual to Cancer Treatment Trials

Multi-level approach will leverage digital tools and community outreach to increase education on trials and enrollment Read More

Moffitt Researchers Identify Factors Associated with COVID-19 Vaccination Acceptance Among Cancer Patients

High acceptors were more confident in the effectiveness and safety of the vaccine Read More

Genomic Testing Can Identify African American Prostate Cancer Patients Who Have High-Risk Disease

African American men are twice as likely to have more aggressive disease compared to non-African American men Read More

Moffitt Cancer Center and Deerfield Management Launch Bayfield Therapeutics

Deerfield commits up to $130 million over 10 years to accelerate Moffitt’s innovative drug discovery research Read More

Dual Checkpoint Inhibitor Blockade Shows Promise as First-Line and Salvage Therapy for Merkel Cell Carcinoma Patients

Phase 2 study results show an exceptional response to nivolumab and ipilimumab combo therapy, no additional benefit when adding stereotactic body radiation therapy Read More

Moffitt Researchers Use Computer Modeling to Understand How Self-Renewal Processes Impact Skin Cell Evolution

Subclone size is due to persistence with larger subclones arising early in life Read More

Moffitt Physicians Lead International Study to Identify Melanoma Patients with High-Risk Disease

Stage 3A melanoma patients with larger sentinel node micrometastases have poorer outcomes and may benefit from adjuvant therapy Read More

Moffitt Researchers Discover Cancer-associated Fibroblasts Induce Drug Sensitivity

Understanding the competing tumor suppressing and promoting effects of these fibroblasts could lead to more effective therapies Read More

Moffitt Researchers Use Mathematical Modeling to Explain Immunotherapy Responses

The size of tumor and immune cell populations and their interactions over time impact outcomes to treatment Read More

Moffitt Researchers Discover DNA Copy Number Alterations Lead to Changes in RNA Circuits that Impact Melanoma Metastasis

Gains in chromosome 1q stimulate a network of competitive endogenous RNA molecules that promote melanoma metastasis Read More

Moffitt Researchers Identify Pathway that Regulates Angiogenesis in Tumors

Signaling through the protein YAP1 controls angiogenesis under normal and low oxygen conditions Read More

Moffitt Researchers Identify Splice Variant Biomarkers in Clear Cell Renal Cell Carcinoma

Survival risk tool based on expression of splice variants identifies patients at high risk of poor outcomes Read More

Turnstone Biologics and Moffitt Cancer Center Announce Strategic Alliance to Advance Next-Generation TIL Therapies for Solid Tumors

Strategic alliance significantly expands ongoing multi-year collaboration by granting Turnstone broader access and enhanced benefits at Moffitt Read More

Moffitt Study Shows Adaptive Therapy Improves Outcomes, Reduces Care Costs for Prostate Cancer Patients

Using evolutionary principles and mathematical modeling to outline an intermittent therapy approach using abiraterone can save patients as much as $70,000 Read More

Moffitt Researchers Determine 1st Crystal Structure of LAG3

The discovery reveals how the protein binds to ligands and inhibitory antibodies, and will improve cancer drug discovery Read More

Moffitt Researchers Contribute to Discovery of Mechanism Leading to Drug Resistance in Prostate Cancer

Consecutive molecular modifications of the androgen receptor can contribute to drug resistance, which can be blocked with an ACK1 inhibitor Read More

Moffitt Researchers Identify Tumor-Based Methylation Patterns as Cancer Biomarkers

These patterns predict the composition of the tumor immune environment and patient outcomes Read More

Moffitt Researchers Identify Pathway that Regulates Lipid Synthesis and Contributes to Tumor Survival

The alterations are associated with poor outcomes and disease progression Read More

Moffitt Researchers Identify Key Factors Impacting Adaptive Therapy

Spatial organization and competition between drug-resistant cells affect treatment outcomes Read More

Moffitt Researchers Discover New Target for CAR T Cells in Solid Tumors

Chimeric antigen receptor T cells that target OR2H1 inhibit lung and ovarian tumor growth in mice Read More

Moffitt Researchers Develop Model to Predict Patients with Poor Lung Cancer Outcomes

The model uses radiomic features from screening images to inform lesions associated with very poor survival Read More

Moffitt Researchers Identify Key Characteristics of Immune Cells in Ovarian Cancer

Tissue-resident memory T cells are important mediators of immune response Read More

Moffitt Researchers Identify Immunosuppression as a Key Factor Leading to Colorectal Cancer Development

The team used mathematical modeling to characterize the interplay between immune suppression, immune blockade and antigenicity Read More

SpaceX to Take Moffitt Investigators’ Experiment to the International Space Station

Their company, Cadw Therapeutics, is partnering with SpacePharma to study stress and DNA damage caused by space travel in hopes of developing therapies to prevent it Read More

Moffitt Gets Boost in State Funding to Support Pasco County Project

The new Florida budget awaiting the governor’s signature includes nearly $150 million allocated for the cancer center Read More

COVID Infection Rates in Hillsborough County May Have Been Higher Than Reported at Height of Pandemic

Moffitt study shows COVID prevalence between October 2020 and March 2021 was twofold higher Read More

Moffitt Researchers Perform Comprehensive Analysis of Cellular and Molecular Characteristics of Acral Melanoma

Differences identified between acral and non-acral melanoma may lead to potential therapeutic targets Read More

Moffitt Study Finds Cancer Patients Do Benefit From COVID-19 Vaccination

The rate of developing antibodies varies by cancer type and treatment Read More

Specific Cancer Driving Protein Plays Important Role in Lung Cancer Development, Moffitt Researchers Say

ΔNp63 controls enhancer regions of genes involved in the regulation of cell identity Read More

Moffitt Researchers Analyze VA Data to Study Prostate Cancer Disparities

“Equal access system” shows how African American men are disproportionately affected Read More

Moffitt Researchers Unlock Immune Cell Contributions that Could Lead to New Therapies for Endometrial Cancer

IgA interactions with pIgR govern anti-tumor activity and are associated with improved outcomes Read More

Moffitt Names Dr. Elsa R. Flores Associate Center Director of Basic Science

Flores will oversee the Basic Science Division, which includes the Cancer Physiology, Drug Discovery, Immunology, Molecular Oncology and Tumor Biology departments Read More

Moffitt Researchers Discover Mechanism Controlling Tertiary Lymphoid Structure Formation in Tumors

Finding could potentially enhance response to immunotherapy for tumors that can’t be removed Read More

Moffitt Study Shows Lymphoma Patients Can Benefit from Receiving CAR T Sooner

Using axicabtagene ciloleucel as a second-line treatment provided better outcomes compared to standard of care in phase 3 ZUMA-7 clinical trial Read More

Moffitt Researchers Develop HER3-Specific Dendritic Cell Cancer Vaccine

Study shows it delays tumor growth and prolongs survival in mouse models Read More

Moffitt Researchers Use Computer Modeling to Predict Patient Tumor Responses to Radiation Therapy

New study finds dynamics between immune effector and suppressor cells can help show how radiation will impact a tumor Read More

Moffitt Researcher Receives NIH Director’s New Innovator Award

Ana Gomes, Ph.D., will use the grant to study how aging impacts cancer Read More

Moffitt Cancer Center’s National Cancer Institute Designation Renewed

The cancer center was awarded the NCI’s highest designation, Comprehensive Cancer Center, in recognition of its scientific and clinical impact and research excellence Read More

Patients Treated with Immune Checkpoint Inhibitors Have Better Quality of Life, Moffitt Analysis Shows

Researchers compared self-reported outcomes of patients treated with and without immunotherapy Read More

Moffitt Cancer Center Joins Dana-Farber Cancer Institute to Help Stop Blood Cancer

Health care initiative aims to provide free screening to adults with higher risks for multiple myeloma Read More

Moffitt Researchers Develop Model to Predict Non-Small Cell Lung Cancer Patient Outcomes to Immunotherapy

Model uses radiomic feature associated with low oxygen in tissues combined with clinical parameters Read More

Adoptive Cell Therapy Plus Checkpoint Inhibitors Show Promise in Non-Small Cell Lung Cancer

Moffitt-initiated pilot study finds patients with checkpoint inhibitor resistant tumors are responding to tumor infiltrating lymphocyte treatment Read More

Moffitt Researchers Show Beta-Cutaneous HPV May Be Predictor of Squamous Cell Carcinoma

Study finds this HPV type and UV exposure increase skin cancer risk Read More

Novel Therapy Shows Promise for Lung Cancer Patients with Rare EGFR Mutation

Amivantamab, an EGFR-MET biospecific antibody, has already received Breakthrough Therapy Designation by the FDA Read More

Moffitt Researchers Identify New Relevant Target for PARP Inhibitor Talazoparib

PARP16 is a novel functionally relevant target for talazoparib that enhances anti-cancer effects when drug is used alone or in combination with adavosertib Read More

Moffitt Cancer Center Physician Receives NCI Cancer Clinical Investigator Team Leadership Award

Zeynep Eroglu, M.D., will receive funding to support clinical and research efforts Read More

Moffitt Receives $10.2 Million Grant to Develop New Lung Cancer Therapies

Four distinct research projects will investigate common metabolic pathways that can be targeted therapeutically Read More

An Educational Intervention Can Help Vapers Use Their E-Cigarettes to Quit Smoking, Moffitt Study Finds

Researchers say results could help expand the public health potential of e-cigarettes Read More

Moffitt Researchers Develop Non-invasive Approach to Measure Biomarker Levels, Predict Outcomes in Lung Cancer Patients

New data shows computer models based on deep learning of PET/CT images can measure PD-L1 expression Read More

Analyzing the Tumor Microenvironment at the Single Cell Level Sheds Light on Metastatic Melanoma Outcomes, Moffitt Study Shows

Findings may help better direct targeted treatments by identifying patient response in advance of therapy Read More

Moffitt Cancer Center Experts to Present New Clinical Research Data

American Society of Clinical Oncology virtual conference is June 4-8 Read More

Moffitt Cancer Center Partners with Top Cancer Centers for Urgent Call to Get Cancer-Preventing HPV Vaccination Back on Track

The COVID-19 pandemic has interrupted delivery of key health services for children and adolescents, including HPV vaccination for cancer prevention. Read More

Moffitt Researchers Discover Regulatory Pathway That Blocks Immune Response Against Cancer

Preclinical study finds TIM-3 suppresses DNA uptake and STING signaling Read More

Moffitt Investigators Identify STING Gene Methylation Allows Melanoma to Evade the Immune System

Findings lead to the development of therapeutic strategies to overcome it Read More

Moffitt Researchers Demonstrate Tissue Architecture Regulates Tumor Evolution: Location Matters

Spatial constraints from the surrounding environment govern the evolution of tumors Read More

Moffitt Researchers Use Mathematical Modeling to Analyze Dynamics of CAR T-Cell Therapy

Competition with normal T cells and random extinction events influence patient outcomes Read More

Moffitt Researchers Show Sequential Treatment with Immunotherapy and Targeted Therapy Prolongs Anti-Tumor Activity

Immunotherapy followed by BRAF and MEK inhibitors promotes anti-tumor immunity and suppresses signaling that leads to drug resistance Read More

Lung Cancer Cells Have Differential Signaling Responses to KRAS Inhibitor Treatment with Important Implications for Emerging Clinical Trials

Moffitt researchers find epithelial and mesenchymal subtypes of lung cancer cells respond differently to KRASG12C inhibitor therapy Read More

Moffitt Researchers Use Mathematical Modeling to Identify Factors that Determine Adaptive Therapy Success

Cell turnover and cost of resistance are important factors that impact adaptive therapy Read More

Moffitt to Share Research Update on Cancer in the Black Community

Feb. 11 virtual event will highlight scientific advancements of health disparities research funded through the George Edgecomb Society Read More

Moffitt Researchers Discover Mechanism that Regulates Anti-Tumor Activity of Immune Cells in Ovarian Cancer

IgA regulates immune cell activity by inhibiting RAS signaling and recognizing tumor markers Read More

Moffitt Researchers Identify How Cancer Cells Adapt to Survive Harsh Tumor Microenvironments

Activation of certain transcription factors allow cells to select for a Warburg phenotype Read More

Study Identifies Exposure to Common Food-Borne Pathogen Linked to Rare Brain Cancer

Researchers say people who have glioma are more likely to have antibodies to T. gondii Read More

Inflammation from Androgen Deprivation Therapy May Cause Fatigue in Prostate Cancer Patients

Moffitt Cancer Center study suggests elevation in inflammation marker IL-6 linked to higher levels of fatigue Read More

Moffitt Researchers Discover Potential New Drug Target to Treat Cutaneous T Cell Lymphoma

Drug that blocks methylation restores SATB1 expression and may be effective against disease Read More

Moffitt Researchers Identify Genomic and Immune Indicators That Predict Lethal Outcomes in High-Grade Prostate Cancer

Together, immune content and Decipher scores can help determine which patients could benefit from targeted therapies Read More

Moffitt Program Bringing Patients, Scientists Together Infuses New Meaning into Research

The Patient Researcher Forum allows patients and researchers to learn from one another Read More

Moffitt Researchers Develop Tool to Better Predict Treatment Course for Lung Cancer Patients

The PET/CT-based deep learning model classifies EGFR mutation status in non-small cell lung cancer, identifying which treatment option is best Read More

Moffitt Researchers Discover Specific Molecules that Promote Cancer Progression

TAp63 regulates long noncoding RNA molecules that promote tumor development by activating AKT Read More

Moffitt Cancer Center Study Educates Oncologists on LGBTQ+ Health Concerns

The COLORS Training Program provides knowledge about LGBTQ+-related issues to help doctors better understand their patients’ needs Read More

Moffitt Researchers Identify Driver of Further Metastasis in BRAF Inhibitor Resistant Melanoma

The discovery could lead to development of new treatment strategies to help patients with advanced melanoma Read More

Acidic Niche Keeps Lymphatic System in Check during Immune Response, Moffitt Researchers Say

Low pH in lymph nodes inhibits effector T cells, while still allowing T cell activation Read More

George Simon, M.D., Named Executive Director of Moffitt Cancer Center-AdventHealth joint Clinical Research Unit

New facility at AdventHealth Celebration offers cancer patients access to cutting-edge treatment and clinical trials Read More

Moffitt Cancer Center Names Vice Chair of Immunology Department

Dorina Avram, Ph.D., brings strong immunology background and leadership to the new role Read More

Moffitt Cancer Center Announces Chair of New Machine Learning Department

Dr. Issam El Naqa will lead efforts to develop and apply machine learning techniques across the spectrum of cancer research Read More

Moffitt Researchers Identify Factors to Predict Severe Toxicities in CAR T Patients

Cytokines levels and the tumor microenvironment pre-treatment could play a key role Read More

Moffitt Researchers Develop Tool to Detect Patients at High Risk for Poor Lung Cancer Outcomes

The novel radiomics model can help identify which early stage lung cancer patients may need aggressive follow-up and/or adjuvant therapy Read More

Moffitt Cancer Center Leader Named to National Cancer Advisory Board

Susan Vadaparampil, Ph.D., M.P.H., appointed to role by President Donald Trump Read More

Moffitt Cancer Center Study Suggests More Could Benefit from CAR T-Cell Therapy

The largest report of commercial CAR T therapy for lymphoma demonstrates its effectiveness even in patients that would not have been eligible for clinical trials Read More

Moffitt Cancer Center Names New Clinical Science Research Leaders

Drs. Eric Haura and Nikhil Khushalani will guide the cancer center’s clinical science, clinical trials and expansion Read More

Moffitt Cancer Center Appoints John Cleveland as New Center Director

John Cleveland, Ph.D., has been named center director and executive vice president of Moffitt Cancer Center, one of 51 National Cancer Institute-designated comprehensive cancer centers in the country and the only one based in Florida. Read More

Moffitt Researchers Identify Molecular Pathway That Controls Immunosuppression in Tumors

PERK protein controls myeloid-derived suppressor cells immunosuppression and may be an effective therapeutic target Read More

Moffitt Researchers Develop Mathematical Model to Predict Patient Outcomes to Adaptive Prostate Cancer Therapy

The model, based on changing levels of the biomarker PSA, can forecast patient responses to intermittent androgen deprivation therapy Read More

Moffitt Researchers Identify Novel Therapeutic Targets in Cutaneous Squamous Cell Carcinoma

Delivery of certain microRNAs or targeting AURKA may be effective approaches for treatment Read More

Moffitt Researchers Discover Novel Role of Specific Histone Deacetylase in Non-Small Cell Lung Cancer

Inhibition of HDAC11 blocks cancer stem cell self-renewal and overcomes drug resistance Read More

Augmented Reality Could Put Smoking Cessation in the Palm of Your Hand

Moffitt Cancer Center partners with Haneke Design to develop AR-based app for innovative smoking cessation study Read More

Krystyna Kowalczyk Named CEO of Moffitt Cancer Center’s Immunotherapy Contract Research Organization

Kowalczyk brings more than 30 years of clinical research operations and management experience to Moffitt Read More

Moffitt Researchers Identify Molecular Characteristics of Leptomeningeal Melanoma Metastases

The microenvironment of leptomeningeal melanoma metastases is enriched for molecules critical to melanoma cell survival and growth Read More

Melanoma Variability at the Single-Cell Level Predicts Treatment Responses, Say Moffitt Researchers

Leveraging tumor cell variability through adaptive treatment strategies maintains drug sensitivity Read More

Post-Traumatic Stress Disorder Linked to Increased Risk of Ovarian Cancer

New study suggests women who experience multiple PTSD symptoms have a much greater risk of developing the disease years later Read More

New Drug Combination Shows Promising Activity in Non-Small Cell Lung Cancer Patients

Moffitt Cancer Center study finds combination treatment of pembrolizumab and vorinostat is well tolerated, showing preliminary efficacy of therapy Read More

Moffitt Researchers Develop Model to Personalize Radiation Treatment for Breast Cancer Patients

The genomically-adjusted radiation dose (GARD) can predict risk of local tumor recurrence and optimize radiation dose Read More

Moffitt Researchers Complete Largest Genomic Analysis of Merkel Cell Carcinoma Patients

Two distinct populations of Merkel cell carcinoma identified; both exhibit similar responses to immunotherapy Read More

Moffitt Researchers Discover Possible New Treatment Strategy for Lung Cancer

Combination therapy targeting KRAS mutation could provide benefit to nearly a third of lung cancer patients Read More

Moffitt Researchers Identify Subtypes of Squamous Cell Lung Cancer

The subtypes have different genetic, chromosomal and protein alterations that could present therapeutic opportunities Read More

Despite Treatment, Elderly Cancer Patients Have Worse Outcomes if HIV-Positive

New study investigates disparity in cancer-related mortality among patients 65 or older with and without HIV Read More

Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA Approval

Studies to expand its use in other cancers are ongoing at Moffitt Cancer Center Read More

Moffitt Researchers Identify Effective Drug Combination Against Uveal Melanoma in Preclinical Studies

The subtypes have different genetic, chromosomal and protein alterations that could present therapeutic opportunities Read More

Researchers Pinpoint Why Lymphoma Patients May Become Resistant to Specific Therapy, Identify Strategy to Overcome It

Loss of the BCL-2 amplicon and transcriptional reprogramming contribute to resistance to the drug Venetoclax® for those with B-cell lymphomas Read More

Moffitt Cancer Center Studies How E-Cigarettes Help Smokers Quit

Smokers who also vape e-cigarettes can help with research effort Read More

Moffitt Cancer Center Showcases Research and Innovation at 13th Annual Business of Biotech Conference

ABC News Political Commentator Cokie Roberts to host interview-style keynote address with Dr. Reid Huber Read More

Moffitt Researchers Characterize Mechanism of Action of CAR T Cells

Signaling properties and activity of CAR T cells are conditioned by the length of the CAR intracellular domain Read More

Researcher Spotlight Katarzyna Rejniak 890X510

Researcher Spotlight: Katarzyna Rejniak Says Teaching is Most Rewarding When Students are Recognized

She leads a computational lab that models the mechanisms of interaction between tumors and their microenvironments Read More

Moffitt Cancer Center Leads the Nation in Addressing LGBTQ Health Care Disparities and Education

Disparities experienced by LGBTQ patients, especially in cancer care, can lead to poorer outcomes and overall health. Read More

Moffitt Researchers Identify Novel Mechanism to Thwart KRas-driven Tumor Growth

Suppression of GSK3 inhibits growth of KRas-driven tumors from pancreatic cancer patients who relapsed after chemotherapy or radiation. Read More

Moffitt Welcomes Nobel Laureate for Ted Couch Cancer Research Lecture Series

Phillip A. Sharp, Ph.D., will give lecture on his Nobel Prize winning cancer research Read More

Evidence Mounts Linking Aspirin to Lower Risk of Ovarian Cancer

New JAMA Oncology study shows daily use can reduce risk by 23 percent Read More

Early PSA Testing Could Help Predict Prostate Cancer among Black Men

New study suggests midlife PSA testing is key to predicting aggressive prostate cancer Read More

Moffitt Researchers Use New Technique to Identify a Novel Drug Combination for Non-Small Cell Lung Cancer

Combining functional proteomics with deep network analysis leads to discovery of new drug target combination Read More

Non-Small Cell Lung Cancer Patients See Improved Survival with Durvalumab

New data from the PACIFIC phase 3 trial published in the New England Journal of Medicine Read More

Moffitt Researcher Awarded World Molecular Imaging Society Gold Medal

Dr. Robert Gillies honored for a lifetime of research in cancer imaging Read More


Researcher Spotlight: Vince Luca, PhD on Receptors, Ligands and the Fate of Cells

Behind the scenes, the Luca Lab studies the "molecular language" of cell-to-cell communication using cutting edge approaches in structural, cellular and synthetic biology. Read More

Moffitt Cancer Center Researchers Compare Chemotherapy Regimens for Best Outcomes in Invasive Bladder Cancer

Less-frequently used combination associated with better response than standard of care Read More

New Studies Show Daily Aspirin Use Reduces Ovarian Cancer Risk and Improves Survival after Diagnosis

Research suggests reducing inflammation through daily aspirin use can lower ovarian cancer risk and improve survival for those battling the disease Read More


Should I Be Worried About Wearing Deodorant?

Even though many people use the terms "antiperspirant" and "deodorant" interchangeably, antiperspirants are actually a subset of deodorants, and each works in a different way. Read More


Research Spotlight: Dr. Yamoah on the 'Lifelong Commitment' of a Physician Scientist

Dr. Kosj Yamoah, a physician-scientist, tracks his roots of studying prostate cancer disparities through his native Ghana. Read More


Moffitt’s Top Research Developments of 2017: New Hope for Aggressive Leukemia

Patients with certain fast-progressing and deadly types of acute myeloid leukemia (AML) saw the first new drug for their disease in more than 40 years approved by the FDA. Read More


Moffitt’s Top Research Developments of 2017: Less is More: Adaptive Therapy

The fourth one on the list of Moffitt research developments for 2017 involves rethinking drug resistance with a strategy called adaptive therapy that links the frequency, dosage and type of chemo to the tumor’s response. Read More


Moffitt’s Top Research Developments of 2017: New Targets for Existing Cancer-Fighting Drugs

The third item on the list of Moffitt research developments for 2017 involves new targets for existing cancer-fighting drugs. Read More


Moffitt’s Top Research Developments of 2017: Novel Combination Approach to Lung Cancer Wins Moffitt a Stand Up To Cancer Grant

The second one on the list of Moffitt research developments involves a grant to study how immunotherapy can change the way the cancer center is treating lung cancer. Read More


Moffitt’s Top Research Developments of 2017: CAR T Therapy Tested, Commercially Available at Moffitt

The first one on the list of Moffitt's top research developments for 2017 is the FDA approval of CAR T therapy for certain aggressive types of adult lymphoma. Read More


Behind the Science: Test May Help Lung Cancer Patients Choose Best Treatment

Lung cancer is by far the leading cause of cancer death among both men and women. More than 220,000 Americans are diagnosed with lung cancer every year. Read More


Behind the Science: 'Super Molecules’ Show Promise in Prevention of Metastatic Breast Cancer

What if a drug commonly used to protect bones from osteoporosis could be altered to keep out breast cancer cells? That’s the goal one Moffitt researcher is pursuing through the creation of "Smart Molecules." Read More


Moffitt and Tampa Bay Rays Lead Relief Mission to Puerto Rico

More than 30,000 pounds of medical and hurricane supplies, generators, food and water are on a chartered Boeing 737 headed for Puerto Rico, which was devastated by Hurricane Maria. Read More


Research Spotlight: Dr. Abate-Daga Discusses the Progress of Immunotherapy

Dr. Daniel Abate-Daga's research is focused on the development of T cell-based immunotherapies for the treatment of cancer. Read More


Research Spotlight: Dr. Enderling Shares Why He Participated in Miles for Moffitt

Dr. Enderling is an assistant member in the Integrated Mathematical Oncology Department. Find out what his team accomplished at Miles for Moffitt this year. Read More


Research Spotlight: Dr. Cress Offers Insights on Molecular Oncology, SPARK Program

Dr. Doug Cress is an associate member of the Molecular Oncology Department. Learn more about his role in Molecular Oncology and the Spark Program. Read More


Research Spotlight: Dr. Gonzalez Aims to Improve Quality of Life for Patients

"We have all had loved ones who've been touched by cancer. I remember being struck by the huge quality of life burden that cancer patients and survivors face," says Dr. Gonzalez. Read More


Dr. Locke: CAR-T Cell Therapy a 'Revolution in Cancer Care'

Dr. Locke, the principal investigator for a new experimental immunotherapy called CAR T-cell therapy, talks about the breakthroughs with this type of treatment. Read More


LGBTQ Patients Priority for Continued Research

The health care needs of LGBTQ patients who are at risk or fighting cancer are a priority for continued research, Moffitt Cancer Center’s Gwendolyn Quinn, PhD, and Matthew Schabath, PhD, told prior to World Cancer Day on Feb. 4. Read More


Infographic: Making Medicine Personal - The Practice of Personalized Medicine

At Moffitt Cancer Center we look at every patient’s cancer as unique. Our clinical expertise and transformational research keeps us at the forefront of personalizing cancer care. Read More


Important HPV Study Comes to an End

After 12 years, a significant study at Moffitt has come to an end. Read More


Moffitt Hosts Cancer Moonshot Summit

Moffitt Cancer Center hosted a Cancer Moonshot Summit bringing together physicians, scientists, patients, and advocates to discuss viable ways to accelerate cancer research and improve treatment. Read More


National Cancer Research Month – How You Can Help

May is National Cancer Research Month, which serves as an important reminder to everyone that the key to future progress in the fight against cancer lies in the critical work that still needs to be done. Read More


Moffitt Eager to Play Role in Biden's 'Moon Shot' to Cure Cancer

Moffitt Eager to Play Role in Biden's 'Moon Shot' to Cure Cancer Read More